A randomized controlled clinical trial to evaluate safety and efficacy of a Unani formulation in the management of Kalaf (Melasma).

MASI Unani herbal hyperpigmentation melanin quality of life

Journal

Journal of complementary & integrative medicine

ISSN: 1553-3840

Titre abrégé: J Complement Integr Med

Pays: Germany

ID NLM: 101313855

Informations de publication

Date de publication:
01 Mar 2023

Historique:

received: 10 08 2021

accepted: 21 09 2021

pubmed: 29 9 2021

medline: 29 9 2021

entrez: 28 9 2021

Statut: epublish

Résumé

Kalaf (Melasma) is an acquired facial hypermelanism. It has direct impact on patient's quality of life and leads to development of various personality disorders. Lack of effective treatment and recurrences have drawn the attention of researcher to find alternative treatment. This study aimed to evaluate safety and efficacy of a topical Unani formulation in the management of melasma. We conducted a prospective randomized controlled clinical study on the participants diagnosed with melasma. The participants (n=72) randomized into test (n=36) and control (n=36) groups. Sixty participants (n=30 in each group) completed the duration of therapy. The participants of the test group were treated with a classical Unani formulation and control group with hydroquinone 4%. The primary end point was change in mean MASI score and secondary end point was improvement in quality of life after eight weeks of treatment. The Unani formulation reduced 40.5% mean MASI score (17.31 ± 9.58 to 10.28 ± 5.92) in comparison to 32% reduction in mean MASI score (20.58 ± 9.49 to 13.92 ± 7.38) in the control group after eight weeks of treatment. When comparing with baseline the difference in MASI score was found statistically significant in both groups (p<0.05). On intergroup comparison, the change in MASI score between both groups was not statistically significant (p>0.05). In addition, MQOL and DQLI also improved significantly in both groups. This study concluded that the Unani formulation and the control drug were equally effective and safer in the management of melasma.

Identifiants

DOI: 10.1515/jcim-2021-0353 PMID: 34582636

pubmed: 34582636

pii: jcim-2021-0353

doi: 10.1515/jcim-2021-0353

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

233-240

Informations de copyright

Références

Bagherani, N, Gianfaldoni, S, Smoller, B. An overview on melasma. J Pigment Disord 2015;2:1–18. https://doi.org/10.4172/2376-0427.1000216 .

doi: 10.4172/2376-0427.1000216

Coban, M. Quality of life of the patients with melasma. J Cosmetol Trichol 2018;4:1–4. https://doi.org/10.4172/2471-9323.1000133 .

doi: 10.4172/2471-9323.1000133

Kristlova, H. Melasma in men. J Pigment Disord 2014;S1:004. https://doi.org/10.4172/JPD.S1-004 .

doi: 10.4172/JPD.S1-004

Sarkar, R, Arora, P, Garg, VK, Sonthalia, S, Gokhale, N. Melasma update. Indian Dermatol Online J 2014;5:426–35. https://doi.org/10.4103/2229-5178.142484 .

doi: 10.4103/2229-5178.142484

Bandyopadhyay, D. Topical treatment of melasma. Indian J Dermatol 2009;54:303–9. https://doi.org/10.4103/0019-5154.57602 .

doi: 10.4103/0019-5154.57602

Kaliterna, D, Zuzul, K, Kovacevic, I. Melasma-review of current treatment modalities and efficacy assessment of a new resorcinol-based topical formulation. J Clin Cosmet Dermatol 2017;1:1–4. https://doi.org/10.16966/2576-2826.116 .

doi: 10.16966/2576-2826.116

LeBon, B, Beynon, TA, Whittaker, SJ. Referral to palliative care services can be encouraged at any stage of the disease to optimize symptom control outcomes. World Health 2007;325:330.

Shankar, K, Godse, K, Aurangabadkar, S, Lahiri, K, Mysore, V, Ganjoo, A, et al.. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther 2014;4:165–86. https://doi.org/10.1007/s13555-014-0064-z .

doi: 10.1007/s13555-014-0064-z

Sarkar, R, Puri, P, Jain, RK, Singh, A, Desai, A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol 2010;24:768–72. https://doi.org/10.1111/j.1468-3083.2009.03524.x .

doi: 10.1111/j.1468-3083.2009.03524.x

Achar, A, Rathi, SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol 2011;56:380–2. https://doi.org/10.4103/0019-5154.84722 .

doi: 10.4103/0019-5154.84722

Handel, AC, Miot, LDB, Miot, HA. Melasma: a clinical and epidemiological review. An Bras Dermatol 2014;89:771–82. https://doi.org/10.1590/abd1806-4841.20143063 .

doi: 10.1590/abd1806-4841.20143063

Hexsel, D, Lacerda, DA, Cavalcante, AS, Filho, CA, Kalil, CL, Ayres, EL, et al.. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol 2014;53:440–4. https://doi.org/10.1111/j.1365-4632.2012.05748.x .

doi: 10.1111/j.1365-4632.2012.05748.x

Sarkar, R, Ailawadi, P, Garg, S. Melasma in men: a review of clinical, etiological, and management issues. J Clin Aesthetic Dermatol 2018;11:53–9.

Yalamanchili, R, Shastry, V, Betkerur, J. Clinico-epidemiological study and quality of life assessment in melasma. Indian J Dermatol 2015;60:519. https://doi.org/10.4103/0019-5154.164415 .

doi: 10.4103/0019-5154.164415

Arora, P, Sarkar, R, Garg, VK, Arya, L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthetic Surg 2012;5:93–103. https://doi.org/10.4103/0974-2077.99436 .

doi: 10.4103/0974-2077.99436

D’Mello, SA, Finlay, GJ, Baguley, BC, Askarian-Amiri, ME. Signaling pathways in melanogenesis. Int J Mol Sci 2016;17:1144. https://doi.org/10.3390/ijms17071144 .

doi: 10.3390/ijms17071144

Latif, A, Zafer, N, Abdullah. Randomized clinical trial of Unani formulations in melasma/chloasma. Hippocratic J Unani Med 2012;7:19–31.

Arora, P, Meena, N, Sharma, PK, Raihan, M. Impact of melasma on quality of life in Indian patients. Pigment Int 2017;4:92–7. https://doi.org/10.4103/2349-5847.219683 .

doi: 10.4103/2349-5847.219683

Jiang, J, Akinseye, O, Tovar-Garza, A, Pandya, AG. The effect of melasma on self-esteem: a pilot study. Int J Wom Dermatol 2018;4:38–42. https://doi.org/10.1016/j.ijwd.2017.11.003 .

doi: 10.1016/j.ijwd.2017.11.003

Ogbechie-Godec, OA, Elbuluk, N. Melasma: an up-to-date comprehensive review. Dermatol Ther 2017;7:305–18. https://doi.org/10.1007/s13555-017-0194-1 .

doi: 10.1007/s13555-017-0194-1

Anonymous. Qarabaddin-e- Azam-Wo-Akmal . New Delhi: Central Council for Research in Unani Medicine; 2005:395 p.

Sealed Envelope Ltd. Create a blocked randomisation list; 2021. https://sealedenvelope.com/simple-randomiser/v1/lists [Accessed 19 Mar 2021].

Faul, F, Erdfelder, E, Lang, AG, Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91.

Theplantlist. The plant list, 2013 version 1.1; 2021. http://www.theplantlist.org/ [Accessed 19 Mar 2021].

Kavya, M. Melasma: a clinico-epidemiological study. Int J Basic Appl Med Sci 2014;4:388–91.

Pichardo, R, Vallejos, Q, Feldman, SR, Schulz, MR, Verma, A, Quandt, SA, et al.. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol 2009;48:22–6. https://doi.org/10.1111/j.1365-4632.2009.03778.x .

doi: 10.1111/j.1365-4632.2009.03778.x

Sultana, A, Siddiquee, MR, Khanna, N, Ahmad, T, Shiffa, M. Comparative clinical evaluation of Unani formulations in the treatment of melasma. Am J PharmTech Res 2012;2:759–69.

Karrabi, M, David, J, Sahebkar, M. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman’s formula in subjects with epidermal melasma: a randomized, double-blind clinical trial study. Skin Res Technol 2020;27:24–31. https://doi.org/10.1111/srt.12901 .

doi: 10.1111/srt.12901

Khosravan, S, Alami, A, Moghadam, MH, Ramezani, V. The effect of topical use of petroselinum crispum (parsley) vs. that of hydroquinone cream on reduction of epidermal melasma-a randomized clinical trial. Holist Nurs Pract 2017;31:16–20. https://doi.org/10.1097/HNP.0000000000000186 .

doi: 10.1097/HNP.0000000000000186

McKesey, J, Garza, AT, Pandya, AG. Melasma treatment: an evidence based review. Am J Clin Dermatol 2020;21:173–225. https://doi.org/10.1007/s40257-019-00488-w .

doi: 10.1007/s40257-019-00488-w

Kirtikar, KR, Basu, BD. Indian medicinal plants . Dehradun: International Book Distribution; 1918:1420–3 pp.

Ghani, NM. Khazainul Advia . Lahore (Pakistan): Idara Matbuat-i- Sulemani; 1998:171–4, 437–40, 273–6, 255–7 pp.